〔Abstract〕 Objective To investigate the expression and significance of ferroportin(FPN) in hepatocellular carcinoma. Methods The expression of FPN in serum of 41 healthy controls, 48 chronic liver disease patients and 80 hepatocellular carcinoma patients was detected by ELISA, and the correlation between the degree of FPN in hepatocellular carcinoma group and Child-pugh classification, Barcelona(BCLC) staging of hepatocellular carcinoma was analyzed. 46 cases of liver tissue were collected, and the iron deposition and FPN expression of liver tissue were detected by Prussian blue iron staining and immunohistochemistry. Results In serum, there was no significant difference between healthy control group and chronic liver disease group(P>0.05), but the expression of FPN in hepatocellular carcinoma group was significantly higher than that in healthy control group(P<0.001) and chronic liver disease group(P<0.05). The degree of FPN was positively correlated with the grade of Child-pugh, staging of BCLC(P<0.05) and metastasis, but not with tumor size(P>0.05) and number of nodules(P>0.05). The deposition of blue iron particles was found in patients with hepatocellular carcinoma, and the expression of FPN in liver cancer tissue group was significantly higher than that in benign liver disease tissue group(P<0.05). Conclusion FPN is highly expressed in patients with hepatocellular carcinoma, indicating that FPN may play an important role in the occurrence and development of hepatocellular carcinoma, and it can be used as a new target for immunotherapy of hepatocellular carcinoma.